Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

  Arina, Ainhoa ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Adoptive T cell therapy; Cancer; Immunosuppression; Myeloid derived suppressor cells; Tumor associated macrophages

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ADOPTIVE T CELL THERAPY; ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL ENGINEERING; CELL TRANSFER; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MYELOID DERIVED SUPPRESSOR CELL; NEOPLASM; NONHUMAN; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL DESTRUCTION;

EID: 84902596895     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28464     Document Type: Article

References (10)

1. Arina A, Schreiber K, Binder DC, Karrison TG, Liu RB, Schreiber H. Adoptively transferred immune T cells eradicate established tumors despite cancerinduced immune suppression. J Immunol 2014; 192:1286-93; PMID:24367029; http://dx.doi.org/10.4049/jimmunol.1202498
2. Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, Karrison TG, Weichselbaum RR, Rowley DA, Schreiber H. Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res 2012; 18:2526-33; PMID:22415314; http://dx.doi.org/10.1158/1078-0432.CCR-12-0127
3. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10:294-8; PMID:14981514; http://dx.doi.org/10.1038/nm999
4. Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res 2008; 68:1563-71; PMID:18316622; http://dx.doi.org/10.1158/0008-5472.CAN-07-5324
5. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, Kranz DM, Meredith SC, Rowley DA, Schreiber H. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 2013; 23:516-26; PMID:23597565; http://dx.doi.org/10.1016/j.ccr.2013.03.018
6. Schietinger A, Arina A, Liu RB, Wells S, Huang J, Engels B, Bindokas V, Bartkowiak T, Lee D, Herrmann A, et al. Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology 2013; 2:e26677; PMID:24482750; http://dx.doi.org/10.4161/onci.26677
7. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res 2012; 18:5212-23; PMID:22837179; http://dx.doi.org/10.1158/1078-0432.CCR-12-1108
8. Schmidt K, Zilio S, Schmollinger JC, Bronte V, Blankenstein T, Willimsky G. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. Blood 2013; 121:1740-8; PMID:23305737; http://dx.doi.org/10.1182/blood-2012-06-436568
9. Schietinger A, Philip M, Liu RB, Schreiber K, Schreiber H. Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase. J Exp Med 2010; 207:2469-77; PMID:20921286; http://dx.doi.org/10.1084/jem.20092450
10. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Stemke-Hale K, Davies MA, Gershenwald JE, et al.; NISC Comparative Sequencing Program. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011; 43:442-6; PMID:21499247; http://dx.doi.org/10.1038/ng.810